Objective. To investigate the regulation of whole-blood cyclooxygenase-1 and -2 (COX-2 and COX-1) activities by methotrexate (MTX ) in rheumatoid arthritis (RA) patients.
Rheumatoid arthritis (RA) is an autoimmune disease of kidney functions, stomach acid secretion, and inhibiin which inflammation of the cells lining the synovium tion of platelet aggregation [2] . The COX-2 isozyme produces pain, swelling and progressive erosion of the mediates pain [3] and is induced mainly during the synovial joints. Cyclooxygenase (COX ) is an enzyme inflammatory process by monocytes stimulated by cytothat catalyses the conversion of arachidonic acid to kines and mitogens [2, 4] . prostaglandin H 2 , which is further converted to other Recent results from animal models and clinical studies prostaglandins, prostacyclin and thromboxanes [1, 2] .
suggest that COX-2 is up-regulated in inflammatory There are two COX isozymes, called COX-1 and COX-2, joint disease and is a potential therapeutic target in encoded by separate genes. COX-1 is a constitutive arthritis [5] . Rabbits with antigen-induced arthritis enzyme and mediates functions such as the regulation exhibit an increased prostaglandin E 2 (PGE 2 ) level in synovial fluid, which is reduced by previous administration of dexamethasone [6 ] . Immunocytochemical studies Additionally, synovial cells from RA patients produced in an incubator at 37°C for 60 min. Serum was separated by centrifugation (10 min at 3000 r.p.m.) and 100 ml was large amounts of PGE 2 and also showed increased gene expression of COX-2, but not of COX-1 [7] .
removed and added to a tube containing 400 ml methanol. After another centrifugation, supernatant was kept Very limited information is available about the effects of disease-modifying anti-rheumatic drugs (DMARDs) at −70°C until assayed for thromboxane B activities, 250 ml blood from each of six healthy subjects Peripheral whole blood for measurement of COX-2 and was co-incubated with 250 ml serum collected from six -1 activity was collected from 15 patients with RA (12 RA/MTX patients as well as with autologous or heterowomen and three men, aged 57.13 ± 3.28 yr). All logous serum. The assays for COX-1 and COX-2 activitpatients met the American College of Rheumatology ies were performed as described above and the results 1987 revised criteria [8] . Written informed consent was corrected for the dilutions performed. obtained from them before they entered the study. The
Analyses of TxB 2 and PGE 2 . Concentrations of PGE 2 mean duration of the disease was 11.14 ± 2.65 yr.
and TxB 2 were measured by radioimmunoassay using Clinical evaluation was performed at each visit. Pain, commercial kits (DuPont/New England Nuclear NEN@, duration of early morning stiffness, number of swollen Boston, MA, USA) [10]. and/or tender joints, and Westergren sedimentation rate were quantified and combined in an activity score as Statistical analysis described by Wilke et al. [9] (0 = no activity, 8 = Results are expressed as mean ± ... A probability maximal activity). No patient had received concomitant level of <0.05, as assessed by analysis of variance therapy with non-steroidal anti-inflammatory drugs followed by the Newman-Keuls test, was considered (NSAIDs) or glucocorticosteroids within 2 weeks before significant. the study. Twelve patients had a regimen of 5-7.5 mg MTX taken as a single weekly oral dose (RA/MTX Results patients). Three patients were without medication at study entry. Nine healthy volunteers who were sex-and
In vitro effect of MTX on COX-2 and COX-1 activities age-matched served as normal controls. All refrained
The in vitro effects of MTX on COX-1 and COX-2 from taking NSAIDs for at least 2 weeks before donating activities were quantified by measurement of PGE 2 blood. Additionally, six RA patients treated with 250 mg and TxB 2 in the serum of six normal, healthy donors chloroquine daily (RA/CQ patients) were studied; they exposed to different drug concentrations. The results of were similar to the patients treated with MTX with in vitro assays showed no direct action of any dose of respect to age (53 ± 4.01 yr) and disease duration MTX on the activity of either enzyme (COX The results of the analysis of whole-blood COX-2 and COX-1 activities in 12 RA/MTX patients, six RA/CQ Germany) was previously diluted in phosphate-buffered saline (PBS) and 2 ml of each solution was added to the patients and nine matched normal controls are presented in Fig. 1 . Our results clearly show that the use of MTX vials. The final concentrations of MTX in the assay were 10−4, 10−5, 10−6, 10−7 and 10−8 , and a control by RA patients promoted preferential inhibition of COX-2 activity. RA patients treated with CQ showed tube was incubated with 2 ml PBS. Normal human venous blood was collected with no anticoagulant, and PGE 2 values within the normal range, similar to those obtained with whole blood collected from normal donors 500 ml was immediately added to each tube containing 2 ml test substance. The tubes were vortexed and placed and significantly different from those obtained in RA/MTX serum. The co-incubation with autologous or heterologous serum did not interfere with enzyme activity. No inhibitory influence of RA/MTX serum on COX-1 activity was detected.
Discussion
The aim of this study was to test the effect of low-dose methotrexate on COX-2 and COX-1 activities using a whole-blood assay [10] . This assay simulated the physiological responses of humans to drug administration, thereby resulting in a more accurate ex vivo measurement of the ability of a drug to inhibit COX-2 and COX-1 activities [10, 11, 12, 13]. We tested the in vitro action showed PGE 2 production within the normal range, similar to the result obtained with whole blood from RA/MTX patients. The basal plasma concentrations of normal donors. It is worth noticing that the concentra-PGE 2 (without LPS) was not affected by any treatment tion of PGE 2 in the whole blood of three RA patients (4.65 ± 0.9 ng/ml PGE 2 for RA/MTX patients, without medication was similar to that in blood from 4.23 ± 0.56 ng/ml for RA/CQ patients and normal donors (33.52 ng/ml ). Furthermore, we found 6.7 ± 1.03 ng/ml for normal donors). Inhibition of no correlation between prostaglandin levels and the whole-blood COX-1 activity was not found in RA/MTX Wilke activity score. COX-1 activity was not altered by patients or in patients treated with CQ. No correlation MTX or CQ therapy. was found between the Wilke activity score (3.33 ± 0.61)
The results of the in vitro assay performed with and COX-2/COX-1 activities. It should be emphasized different concentrations of MTX showed no direct action that the numbers of circulating monocytes and platelets of the drug on whole-blood COX-2 or COX-1 activities. in all groups of patients were within the normal range, This result probably rules out a direct action of the drug and did not correlate with the level of COX-1 or COX-2 on either enzyme. activity (data not shown).
In order to investigate the influence of serum factors on enzyme activity, whole blood collected from normal Influence of serum factors on COX-1 and COX-2 donors was exposed to RA/MTX, autologous or heteroactivities logous serum during assays for COX-1 and COX-2 In order to investigate the influence of serum factors on activities. The results showed a preferential ability of enzyme activity, whole blood was collected from normal serum from RA/MTX patients to inhibit COX-2 activdonors and exposed to RA/MTX, autologous or heteroity. This inhibition of COX-2 activity, verified only in logous serum during the stimulation of COX-1 and the presence of RA/MTX serum, supports a direct effect COX-2 activity. Results in Table 1 by the following observations. First, whole blood from RA/MTX patients showed a reduction in the concentra- with blood from healthy donors promoted preferential
